We have advised Antiverse on its multi-target partnership and licensing agreement with Nxera Pharma (Nxera) to design antibodies for G-protein coupled receptors (GPCRs) using generative artificial intelligence.
Under the terms of the multi-year agreement, Antiverse will receive an upfront payment and research funding and is eligible for milestone payments. Nxera will retain an exclusive worldwide license to the antibody assets, providing full rights to develop and commercialize the candidates.
Antiverse is an artificial intelligence-driven techbio company specializing in antibody design against challenging targets, including G-protein coupled receptors and ion channels. Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.
Commenting on the transaction, Life Sciences transactions partner, Colin McCall said: "It was great to work with the Antiverse team on this deal with Nxera, which aims to bring transformative therapies for multiple diseases of high unmet need to patients. This is a fantastic opportunity to see the power of their engine in action, using machine learning to design antibodies for challenging to drug targets."
The team consisted of partner Colin McCall and senior associate Charlie Adams in the patents team.
